Rebecca O'connor, DO | |
5424 Grand Blvd, New Port Richey, FL 34652-4008 | |
(727) 845-1736 | |
(727) 849-0759 |
Full Name | Rebecca O'connor |
---|---|
Gender | Female |
Speciality | Anesthesiology |
Experience | 18 Years |
Location | 5424 Grand Blvd, New Port Richey, Florida |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1609074152 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207L00000X | Anesthesiology | OS10953 (Florida) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Cape Coral Hospital | Cape coral, FL | Hospital |
Lee Memorial Hospital | Fort myers, FL | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Us Anesthesia Partners Of Florida Inc | 0345143152 | 786 |
News Archive
FutureNeuro, the SFI Research Centre for Chronic and Rare Neurological Diseases, based at RCSI, has partnered with global biopharmaceutical company, UCB, to unlock the power of healthcare data to inform improvements in clinical care of people with epilepsy.
Researchers from the BC Centre for Excellence in HIV/AIDS and the University of British Columbia today released a comprehensive study revealing that the 2008 IAS-USA therapy guidelines for commencing HIV treatment would create significant benefits for individuals infected with HIV and society as a whole.
The glutathione S-transferase M1 (GSTM1) and glutathione S-transferase T1 (GSTT1) null genotypes have been linked to increased risk of developing cancer. The results regarding the association between GSTM1 and GSTT1 null genotypes and the risk of GC or CRC were contradictory.
AcelRx Pharmaceuticals, Inc. today announced that it has successfully completed an End-of-Phase 2 meeting with the FDA for ARX-01, a drug/device combination product based on the company's proprietary NanoTab(TM) dosage form, which enables delivery of sufentanil by the non-invasive oral transmucosal (sublingual) route.
› Verified 2 days ago
Entity Name | Anesthesiologist Associates Pa |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1306889910 PECOS PAC ID: 8921910027 Enrollment ID: O20031105000469 |
News Archive
FutureNeuro, the SFI Research Centre for Chronic and Rare Neurological Diseases, based at RCSI, has partnered with global biopharmaceutical company, UCB, to unlock the power of healthcare data to inform improvements in clinical care of people with epilepsy.
Researchers from the BC Centre for Excellence in HIV/AIDS and the University of British Columbia today released a comprehensive study revealing that the 2008 IAS-USA therapy guidelines for commencing HIV treatment would create significant benefits for individuals infected with HIV and society as a whole.
The glutathione S-transferase M1 (GSTM1) and glutathione S-transferase T1 (GSTT1) null genotypes have been linked to increased risk of developing cancer. The results regarding the association between GSTM1 and GSTT1 null genotypes and the risk of GC or CRC were contradictory.
AcelRx Pharmaceuticals, Inc. today announced that it has successfully completed an End-of-Phase 2 meeting with the FDA for ARX-01, a drug/device combination product based on the company's proprietary NanoTab(TM) dosage form, which enables delivery of sufentanil by the non-invasive oral transmucosal (sublingual) route.
› Verified 2 days ago
Entity Name | Us Anesthesia Partners Of Florida Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1518910520 PECOS PAC ID: 0345143152 Enrollment ID: O20040129000594 |
News Archive
FutureNeuro, the SFI Research Centre for Chronic and Rare Neurological Diseases, based at RCSI, has partnered with global biopharmaceutical company, UCB, to unlock the power of healthcare data to inform improvements in clinical care of people with epilepsy.
Researchers from the BC Centre for Excellence in HIV/AIDS and the University of British Columbia today released a comprehensive study revealing that the 2008 IAS-USA therapy guidelines for commencing HIV treatment would create significant benefits for individuals infected with HIV and society as a whole.
The glutathione S-transferase M1 (GSTM1) and glutathione S-transferase T1 (GSTT1) null genotypes have been linked to increased risk of developing cancer. The results regarding the association between GSTM1 and GSTT1 null genotypes and the risk of GC or CRC were contradictory.
AcelRx Pharmaceuticals, Inc. today announced that it has successfully completed an End-of-Phase 2 meeting with the FDA for ARX-01, a drug/device combination product based on the company's proprietary NanoTab(TM) dosage form, which enables delivery of sufentanil by the non-invasive oral transmucosal (sublingual) route.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Rebecca O'connor, DO 5424 Grand Blvd, New Port Richey, FL 34652-4008 Ph: (727) 845-1736 | Rebecca O'connor, DO 5424 Grand Blvd, New Port Richey, FL 34652-4008 Ph: (727) 845-1736 |
News Archive
FutureNeuro, the SFI Research Centre for Chronic and Rare Neurological Diseases, based at RCSI, has partnered with global biopharmaceutical company, UCB, to unlock the power of healthcare data to inform improvements in clinical care of people with epilepsy.
Researchers from the BC Centre for Excellence in HIV/AIDS and the University of British Columbia today released a comprehensive study revealing that the 2008 IAS-USA therapy guidelines for commencing HIV treatment would create significant benefits for individuals infected with HIV and society as a whole.
The glutathione S-transferase M1 (GSTM1) and glutathione S-transferase T1 (GSTT1) null genotypes have been linked to increased risk of developing cancer. The results regarding the association between GSTM1 and GSTT1 null genotypes and the risk of GC or CRC were contradictory.
AcelRx Pharmaceuticals, Inc. today announced that it has successfully completed an End-of-Phase 2 meeting with the FDA for ARX-01, a drug/device combination product based on the company's proprietary NanoTab(TM) dosage form, which enables delivery of sufentanil by the non-invasive oral transmucosal (sublingual) route.
› Verified 2 days ago
Paul Gubbini, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 6600 Madison St, New Port Richey, FL 34652 Phone: 352-867-8898 Fax: 352-732-6282 | |
Inayat Lakhani, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5637 Marine Parkway, New Port Richey, FL 34652 Phone: 727-848-1733 | |
Dr. Christian John Laman, DO Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 6600 Madison St, New Port Richey, FL 34652 Phone: 727-842-8468 Fax: 727-843-4522 | |
Minnea Bihari Kalra, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 6600 Madison St, New Port Richey, FL 34652 Phone: 727-842-8468 | |
Miguel Adan De La Garza, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4807 Us Highway 19 Ste 102, New Port Richey, FL 34652 Phone: 727-846-7618 Fax: 727-849-7090 | |
Dr. Gonzalo Andres Martinez, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5424 Grand Blvd, New Port Richey, FL 34652 Phone: 317-709-2125 |